Oracle makes healthcare splash with $28.3 billion purchase of Cerner

Oracle made a big splash in the healthcare space Monday, announcing plans to purchase electronic health records company Cerner for $28.3 billion.

The second largest software company in the world had reportedly been nearing a deal to acquire Kansas City, Missouri-based Cerner on Friday. Oracle’s official all-cash tender offer is for $95 per share in equity, making it the firm’s largest transaction to date.

Company officials say the new acquisition will give medical providers a “new generation” of easy-to-use digital tools, access to information in cloud-based applications, and lower administrative workloads and healthcare costs.

"Working together, Cerner and Oracle have the capacity to transform healthcare delivery by providing medical professionals with better information—enabling them to make better treatment decisions resulting in better patient outcomes," Larry Ellison, chairman and chief technology officer at Oracle, said in a statement.

The move is expected to significantly increase Oracle’s revenue in the coming years, particularly as it expands into additional markets around the world.

Both parties expect the transaction will be finalized in 2022.

"Cerner has been a leader in helping digitize medical care and now it's time to realize the real promise of that work with the care delivery tools that get information to the right caregivers at the right time," President and CEO of Cerner David Feinberg added. "Joining Oracle as a dedicated industry business unit provides an unprecedented opportunity to accelerate our work modernizing electronic health records, improving the caregiver experience, and enabling more connected, high-quality and efficient patient care.”

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.